5987-82-6 Usage
Description
Oxybuprocaine hydrochloride, also known as Benoxinate Hydrochloride, is a local anesthetic agent that belongs to the ester class of anesthetics. It is the monohydrochloride salt of oxybuprocaine and is characterized by its white or almost white, crystalline powder or colorless crystals. Oxybuprocaine hydrochloride is known for its fast onset and short duration of action, making it suitable for various medical applications.
Uses
Used in Ophthalmology:
Oxybuprocaine hydrochloride is used as a local anesthetic in ophthalmology for numbing the surface of the eye. It is particularly useful in various eye procedures, such as diagnostic examinations, minor surgical interventions, and laser treatments, where temporary anesthesia is required to minimize discomfort and ensure patient comfort.
Used in Anticonvulsant Applications:
Oxybuprocaine hydrochloride is also utilized as an anticonvulsant, helping to prevent or control seizures in patients with epilepsy or other conditions that may cause convulsions. Its fast-acting properties make it an effective choice for managing acute seizure episodes and providing relief to patients experiencing seizure-related distress.
Used in Pharmaceutical Formulations:
Under the brand name Dorsacaine, Oxybuprocaine hydrochloride is formulated and marketed by Novartis, a leading pharmaceutical company. It is available in various forms, such as eye drops or ointments, for easy administration and effective treatment of the intended applications.
Originator
Dorsacaine HCl,Dorsey,US,1953
Manufacturing Process
25 grams of 3-oxy-4-nitrobenzoic acid are esterified (ethyl ester) and 26
grams of the ester are dissolved in 200 cc of absolute ether and treated with
7 grams of caustic potash in 20 cc of absolute methanol. The red potassium
phenolate with 7 grams of pure butyl bromide and 7 grams of absolute alcohol
are heated for 5 hours in the oven to 150°C. When cool, the alcohol is
evaporated in vacuo and the butoxy-nitrobenzoic acid ethyl ester is
precipitated with water. The substance is sucked off and saponified for 15
minutes with a solution of 2.5 grams of caustic potash in 30 cc of alcohol on a
water bath. The alcohol is evaporated in vacuo and the 3-butoxy-4-
nitrobenzoic acid is precipitated with hydrochloric acid. It forms needles which
melt at 174°C. 7.9 grams of dry acid are boiled for 45 minutes under a reflux
condenser with 25 cc of thionyl chloride. The excess of thionyl chloride is then
removed in vacuo, and the oil is distilled. The acid chloride has a yellow color
and solidifies.
7.3 grams of the acid chloride are treated with 6.6 grams of diethyl-aminoethanol
in 20 cc of absolute benzene. The mixture is then warmed for 1 hour
on a water bath. When cold, it is treated with a solution of soda and washed
with ether. After drying over potash, the ether and benzene are removed by
distillation and 3-butoxy-4-nitrobenzoic acid diethylamino-ethyl ester is
obtained, having a BP 215°C/2.5 mm.
5.0 grams of this product are hydrogenated in absolute alcohol solution with
fresh Raney nickel. When the absorption of hydrogen ceases (5 hours), the
solution is filtered and the alcohol evaporated in vacuo. The 3-butoxy-4-
aminobenzoic acid diethyl-amino-ethyl ester boils at 215°-218°C at 2 mm
pressure; it is an almost colorless oil.
By precipitation of a solution of the ester in absolute ether with hydrogen
chloride gas, the dihydrochloride is obtained; upon recrystallization from
alcohol/ether, it forms crystals which melt at 196°-197°C.
Therapeutic Function
Local anesthetic
Clinical Use
Benoxinate hydrochloride is a topical anesthetic. Benoxinate hydrochloride ophthalmic solution, 0.4%, was originally permitted in 1953 as Dorsacaine under NDA 08-729. The product was reviewed as part of the Drug Efficacy Study Implementation (DESI), found to be effective, approved and marketed by Dorsey until 1980. An abbreviated new drug application (ANDA) was also approved [Sola Barnes Hind (ANDA 84-149)] and marketed until 1991.
Safety Profile
Poison by subcutaneous route. A topical anesthetic. When heated to decomposition it emits toxic fumes of NOx and HCl.
structure and hydrogen bonding
Oxybuprocaine hydrochloride acts as a local anesthetic and is used in eye drop formulations. Mod. II, the stable polymorphic form, contains two molecules with markedly different conformations (stretched and bent). The 13C CPMAS NMR spectrum of this sample12 showed crystallographic splittings arising from the fact that there are two molecules in the asymmetric unit. An INADEQUATE two-dimensional experiment was used to link signals for the same independent molecule. Of the four ethyl groups attached to NHt nitrogens, one gives rise to unusually low chemical shifts, very different from those of the other three groups. This was attributed to gamma-gauche conformational effects, and confirmed by shielding computations. The oxybuprocaine system is too large for computations performed on the crystallographic unit and the intermolecular shielding effects have to be neglected. Nevertheless, the computed shifts do match the order of the experimental ones. The assignment of 13C signals to specific carbons in the two crystallographically inequivalent molecules of oxybuprocaine polymorph showed the power of NMR crystallography.
Check Digit Verification of cas no
The CAS Registry Mumber 5987-82-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,9,8 and 7 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 5987-82:
(6*5)+(5*9)+(4*8)+(3*7)+(2*8)+(1*2)=146
146 % 10 = 6
So 5987-82-6 is a valid CAS Registry Number.
InChI:InChI=1/C17H28N2O3.ClH/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3;/h8-9,13H,4-7,10-12,18H2,1-3H3;1H
5987-82-6Relevant articles and documents
Synthetic method of oxybuprocaine hydrochloride
-
, (2021/07/31)
The synthetic method comprises the following steps: (1) carrying out etherification reaction on a compound as shown in a formula II and 1-bromobutane to prepare a compound as shown in a formula III; (2) carrying out transesterification on the compound as shown in the formula III and 2-(diethylamino) ethanol under the action of a catalyst, and salifying to prepare a compound as shown in a formula IV; (3) carrying out reduction reaction on the compound as shown in the formula IV and a reducing agent to obtain oxybuprocaine free alkali as shown in a formula V; and (4) carrying out salt forming reaction and devitrification on the oxybuprocaine free alkali as shown in the formula V to obtain the oxybuprocaine hydrochloride as shown in the formula I. The invention further discloses a preparation method of the oxybuprocaine hydrochloride. According to the synthetic method of the oxybuprocaine hydrochloride, the synthetic route step length is proper, the three-step reaction and one-step salification are realized, the high-temperature and high-pressure reaction is avoided, the requirement on equipment is not high, and the synthetic method is suitable for industrial production.
